[Swallowable gastric balloon in obesity]

Luxardo R, Bardach A, Colaci C, Alfie V, Ciapponi A, García Martí S, Augustovski F, Alcaraz A, Pichon-Riviere A
Record ID 32018002331
Original Title: Balón intragástrico deglutible en obesidad
Authors' recommendations: Low-quality evidence suggests that the ElipseTM swallowable gastric balloon system might show a considerable benefit since it results in a total weight loss percentage of about 15% at four months in Grade 1 and 2 obese patients who have previously failed with diet therapy. It also suggests its benefit might be lower in improving metabolic parameters such as triglycerides, LDL cholesterol and glycosylated hemoglobin. The information available does not allow to recommend it in Grade 3 obese patients. As for its safety, evidence suggests the adverse events might be uncommon, but potentially serious.No studies assessing efficacy and/or safety of the ElipseTM gastric balloon system have been found in patients with obesity versus other gastric balloons, pharmacological treatment or bariatric surgery.One economic assessment from Canada demonstrated that using the ElipseTM gastric balloon system alone was not cost-effective when compared with bariatric surgery, but it was, when compared to no treatment. In addition, using it as a bridging intervention to bariatric surgery was cheaper and more effective than bariatric surgery alone. The clinical practice guidelines surveyed and, developed for these identified condition, do not mention the ElipseTM gastric balloon system. In Argentina, the balloon is not considered as part of the therapeutic options included in Act 26,396, which rules coverage of eating disorders or in the Mandatory Medical Program.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Obesity
  • Obesity, Morbid
  • Weight Loss
  • Gastric Balloon
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.